Fund manager Neil Woodford has sold his entire stake in Oxford Sciences Innovation, worth close to $70m, as his funds have come under increasing pressure.

Cisco, Capital One and Citi exited the cybersecurity testing platform in a $250m deal that came in the wake of $33m in venture funding.

Alexandria Real Estate Equities-backed gene-edited seed developer Cibus has withdrawn its IPO application three months after setting a price range that would have raised $107m at the upper end.

Solid tumour treatment developer Atreca has set a $100m target for an initial public offering that will provide GlaxoSmithKline with an exit.

Personalis has filed to list on the Nasdaq Global Market through an offering that would come eight years after the genome sequencing platform was spun out of Stanford University.

The Telstra and Telkom-backed enterprise messaging software provider priced its shares at the foot of the IPO's range but is in line to raise $32.5m when it floats next month.

Karolinska Development-backed regenerative implant producer OssDsign has booked $15.8m after selling out the original issue for its forthcoming listing, and is now looking to generate up to $2.4m from the overallotment.

AIG-backed cancer and genetic disease developer BridgeBio Pharma has filed for a $225m initial public offering on the Nasdaq Global Market.

The genetic drug developer is targeting up to $86m in an IPO that would enable Alexandria Venture Investments to score an exit.

Aurora has announced it is set to buy the lidar system developer, which had raised more than $21m from investors including BMW i Ventures and Toyota AI Ventures.